Cargando…

Advances in stromal cell therapy for management of Alzheimer’s disease

Deposition of misfolded proteins and synaptic failure affects the brain in Alzheimer’s disease (AD). Its progression results in amnesia and cognitive impairment. Absence of treatment is due to excessive loss of neurons in the patients and the delayed effects of drugs. The enhanced pluripotency, prol...

Descripción completa

Detalles Bibliográficos
Autores principales: Srivastava, Rashi, Li, Aidong, Datta, Tirtharaj, Jha, Niraj Kumar, Talukder, Salehikram, Jha, Saurabh Kumar, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576849/
https://www.ncbi.nlm.nih.gov/pubmed/36267273
http://dx.doi.org/10.3389/fphar.2022.955401
_version_ 1784811620880351232
author Srivastava, Rashi
Li, Aidong
Datta, Tirtharaj
Jha, Niraj Kumar
Talukder, Salehikram
Jha, Saurabh Kumar
Chen, Zhe-Sheng
author_facet Srivastava, Rashi
Li, Aidong
Datta, Tirtharaj
Jha, Niraj Kumar
Talukder, Salehikram
Jha, Saurabh Kumar
Chen, Zhe-Sheng
author_sort Srivastava, Rashi
collection PubMed
description Deposition of misfolded proteins and synaptic failure affects the brain in Alzheimer’s disease (AD). Its progression results in amnesia and cognitive impairment. Absence of treatment is due to excessive loss of neurons in the patients and the delayed effects of drugs. The enhanced pluripotency, proliferation, differentiation, and recombination characteristics of stromal cells into nerve cells and glial cells present them as a potential treatment for AD. Successful evidence of action in animal models along with positive results in preclinical studies further encourage its utilization for AD treatment. With regard to humans, cell replacement therapy involving mesenchymal stromal cells, induced-pluripotent stromal cells, human embryonic stromal cells, and neural stems show promising results in clinical trials. However, further research is required prior to its use as stromal cell therapy in AD related disorders. The current review deals with the mechanism of development of anomalies such as Alzheimer’s and the prospective applications of stromal cells for treatment.
format Online
Article
Text
id pubmed-9576849
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95768492022-10-19 Advances in stromal cell therapy for management of Alzheimer’s disease Srivastava, Rashi Li, Aidong Datta, Tirtharaj Jha, Niraj Kumar Talukder, Salehikram Jha, Saurabh Kumar Chen, Zhe-Sheng Front Pharmacol Pharmacology Deposition of misfolded proteins and synaptic failure affects the brain in Alzheimer’s disease (AD). Its progression results in amnesia and cognitive impairment. Absence of treatment is due to excessive loss of neurons in the patients and the delayed effects of drugs. The enhanced pluripotency, proliferation, differentiation, and recombination characteristics of stromal cells into nerve cells and glial cells present them as a potential treatment for AD. Successful evidence of action in animal models along with positive results in preclinical studies further encourage its utilization for AD treatment. With regard to humans, cell replacement therapy involving mesenchymal stromal cells, induced-pluripotent stromal cells, human embryonic stromal cells, and neural stems show promising results in clinical trials. However, further research is required prior to its use as stromal cell therapy in AD related disorders. The current review deals with the mechanism of development of anomalies such as Alzheimer’s and the prospective applications of stromal cells for treatment. Frontiers Media S.A. 2022-10-04 /pmc/articles/PMC9576849/ /pubmed/36267273 http://dx.doi.org/10.3389/fphar.2022.955401 Text en Copyright © 2022 Srivastava, Li, Datta, Jha, Talukder, Jha and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Srivastava, Rashi
Li, Aidong
Datta, Tirtharaj
Jha, Niraj Kumar
Talukder, Salehikram
Jha, Saurabh Kumar
Chen, Zhe-Sheng
Advances in stromal cell therapy for management of Alzheimer’s disease
title Advances in stromal cell therapy for management of Alzheimer’s disease
title_full Advances in stromal cell therapy for management of Alzheimer’s disease
title_fullStr Advances in stromal cell therapy for management of Alzheimer’s disease
title_full_unstemmed Advances in stromal cell therapy for management of Alzheimer’s disease
title_short Advances in stromal cell therapy for management of Alzheimer’s disease
title_sort advances in stromal cell therapy for management of alzheimer’s disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576849/
https://www.ncbi.nlm.nih.gov/pubmed/36267273
http://dx.doi.org/10.3389/fphar.2022.955401
work_keys_str_mv AT srivastavarashi advancesinstromalcelltherapyformanagementofalzheimersdisease
AT liaidong advancesinstromalcelltherapyformanagementofalzheimersdisease
AT dattatirtharaj advancesinstromalcelltherapyformanagementofalzheimersdisease
AT jhanirajkumar advancesinstromalcelltherapyformanagementofalzheimersdisease
AT talukdersalehikram advancesinstromalcelltherapyformanagementofalzheimersdisease
AT jhasaurabhkumar advancesinstromalcelltherapyformanagementofalzheimersdisease
AT chenzhesheng advancesinstromalcelltherapyformanagementofalzheimersdisease